Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 129Recurrence 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 12Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Neoplasm Metastasis 8Leukemia 8Burkitt Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Hodgkin Disease 7Prostatic Neoplasms 6Leukemia, Biphenotypic, Acute 5Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Hematologic Diseases 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Rectal Neoplasms 2

Interventions

Etoposide 5fludarabine phosphate 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Cyclophosphamide 4immunotoxin HA22 3Vorinostat 3Dasatinib 3Tacrolimus 2Polymerase Chain Reaction 2Methylprednisolone 2Lenalidomide 2Interleukin-12 Subunit p35 2Indium 2Flow Cytometry 2Doxorubicin 2Diphenhydramine 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 2Bortezomib 2Bendamustine Hydrochloride 2Amifostine 2Acetaminophen 27-hydroxystaurosporine 2sargramostim 1rasburicase 1pyroxamide 1ontuxizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Hairy Cell × Dexamethasone × Clear all
NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
18 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡